Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the “Meeting”). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual and Special Meeting of Shareholders and Management Information Circular of Greenbrook dated May 24, 2019.
The total number of common shares represented by holders by proxy at the Meeting was 36,752,930, representing approximately 64.55% of Greenbrook’s outstanding common shares entitled to be voted.
Election of Directors
All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders present or represented by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed, without a ballot being conducted. The following represents the proxies received with regard to such matter:
Nominee
|
Votes For
|
% Votes For
|
Votes Withheld
|
% Votes Withheld
|
Brian P. Burke
|
36,498,478
|
99.98%
|
8,500
|
0.02%
|
Colleen Campbell
|
36,506,978
|
100.00%
|
0
|
0.00%
|
Sasha Cucuz
|
36,501,978
|
99.99%
|
5,000
|
0.01%
|
Adrienne Graves, Ph.D.
|
36,504,478
|
99.99%
|
2,500
|
0.01%
|
Bill Leonard
|
36,500,978
|
99.98%
|
6,000
|
0.02%
|
Adele C. Oliva
|
36,506,978
|
100.00%
|
0
|
0.00%
|
Frank Tworecke
|
36,498,478
|
99.98%
|
8,500
|
0.02%
|
Elias Vamvakas
|
36,500,978
|
99.98%
|
6,000
|
0.02%
|
Appointment of Auditors
KPMG LLP was reappointed as auditor of Greenbrook and the directors were authorized to fix the auditor’s remuneration by a resolution passed by a majority of the shareholders present or represented by proxy at the Meeting, without a ballot being conducted. The following represents the proxies received with regard to such matter:
Votes For
|
% Votes For
|
Votes Withheld
|
% Votes Withheld
|
36,746,930
|
99.98%
|
6,000
|
0.02%
|
Amendments to the Stock Option Plan
Certain amendments to Greenbrook’s stock option plan were approved by a resolution passed by a majority of shareholders present or represented by proxy at the Meeting, without a ballot being conducted. The following represents the proxies received with regard to such matter:
Votes For
|
% Votes For
|
Votes Against
|
% Votes Against
|
36,489,778
|
99.95%
|
17,200
|
0.05%
|
Approval of Previously-Granted Stock Options
The grant of 150,000 stock options to a consultant of Greenbrook, as previously approved by Greenbrook’s board of directors, was approved, ratified and confirmed by a resolution passed by a majority of shareholders present or represented by proxy at the Meeting, without a ballot being conducted. The following represents the proxies received with regard to such matter:
Votes For
|
% Votes For
|
Votes Against
|
% Votes Against
|
35,858,778
|
98.22%
|
648,200
|
1.78%
|
About Greenbrook TMS Inc.
Operating through 75 Company-operated treatment centers, Greenbrook is a leading provider of TMS, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 250,000 TMS treatments to over 6,500 patients struggling with depression.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190628005535/en/
Copyright Business Wire 2019